Search company, investor...

Predict your next investment

Corporate Venture
asahikaseiventures.com

Investments

15

Portfolio Exits

2

About Asahi Kasei Ventures

Asahi Kasei is a diversified business based in Tokyo focused on three primary sectors: Materials, Homes and Healthcare. Asahi Kasei Corporate Venture Capital focuses on investing in global companies in areas of strategic importance to Asahi Kasei. The company's mission is to create new long-term business opportunities for Asahi Kasei.

Headquarters Location

4400 Bohannon Drive Suite 240

Menlo Park, California, 94025,

United States

Want to inform investors similar to Asahi Kasei Ventures about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Asahi Kasei Ventures News

Koya Medical Raises $26M in Series B Funding

Feb 3, 2022

Koya Medical, an Oakland, Calif.-based healthcare company focused on advancing lymphatic and venous care through a comprehensive suite of people-centric platforms, closed a $26m Series B financing.The round was led by 3×5 Partners, along with new investors including Asahi Kasei Ventures, Cadence Healthcare Ventures, and existing investors Arboretum Ventures and Scientific Health Development, among others.Led by Andy Doraiswamy, Ph.D., founder, president, and CEO, Koya Medical is a healthcare company developing breakthrough treatments for lymphedema and venous diseases to increase movement, mobility, and personalized care.Dayspring is an active compression treatment that enables movement and mobility cleared by the U.S. Food and Drug Administration (FDA) to treat lymphedema and chronic venous conditions.It is a wearable and mobility-enabled active compression system that enables movement, mobility, and personalized care. Disclaimer: This story is auto-aggregated & summarized by a computer program and has not been created by StartupAround.

Asahi Kasei Ventures Investments

15 Investments

Asahi Kasei Ventures has made 15 investments. Their latest investment was in Swing Therapeutics as part of their Series A on June 6, 2022.

CBI Logo

Asahi Kasei Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/16/2022

Series A

Swing Therapeutics

$10.3M

Yes

2

2/3/2022

Series B

Koya Medical

$26M

Yes

10

6/23/2021

Series B - II

Glycomine

$35M

Yes

12

5/27/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

5/6/2021

Unattributed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/16/2022

2/3/2022

6/23/2021

5/27/2021

5/6/2021

Round

Series A

Series B

Series B - II

Series C

Unattributed VC

Company

Swing Therapeutics

Koya Medical

Glycomine

Subscribe to see more

Subscribe to see more

Amount

$10.3M

$26M

$35M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

10

12

10

10

Asahi Kasei Ventures Portfolio Exits

2 Portfolio Exits

Asahi Kasei Ventures has 2 portfolio exits. Their latest portfolio exit was EnerBee on February 04, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/4/2022

Acquired

$99M

1

7/16/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/4/2022

7/16/2021

Exit

Acquired

IPO

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Sources

1

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.